GSK Plc: DREAMM-3 Phase III Trial For Blenrep Fails To Meet Primary Endpoint

GSK plc (GSK.L,GSK) announced the DREAMM-3, the phase III head-to-head superiority trial of Blenrep monotherapy versus pomalidomide in combination with low dose dexamethasone in patients with relapsed or refractory multiple myeloma, did not meet its primary endpoint of progression-free survival. The safety and tolerability profile of belantamab mafodotin was consistent with the known safety profile, the company noted.

Blenrep was granted accelerated approval by the FDA as a monotherapy for treating adult patients with refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The accelerated approval was based on the results of the DREAMM-2 overall response rate, duration of response and contingent upon a confirmed clinical benefit from a randomised phase III trial.

The Group noted that additional trials within the DREAMM clinical trial programme will continue.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT